A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis

Phase 2 Not yet recruiting 160 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the efficacy and safety of HRS-4729 injection and HRS9531 injection in adult participants with metabolic dysfunction-associated steatohepatitis after 52 weeks of treatment.

Timeline

Start: 2026-07
Primary completion: 2028-03
Completion: 2028-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-4729	Unknown	—	—
Subject	HRS9531	Unknown	—	—

A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis

Summary

Timeline

Drugs

Indications